Pharmacokinetic studies and LC-MS/MS method development of ganciclovir and dipeptide monoester prodrugs in Sprague Dawley rats

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 40, Issue 3, 2015, Pages 325-334

  Gunda, Sriram ^a   Earla, Ravinder ^a   Cholkar, Kishore ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Ganciclovir dipeptide prodrugs; Herpes; LC MS MS; Method; Oral dose; Peptide transporter; Pharmacokinetics

Indexed keywords

DIPEPTIDE; GANCICLOVIR; TYROSYLVALYLGANICLOVIR; UNCLASSIFIED DRUG; VALYLGANICLOVIR; ACICLOVIR; ESTER; PRODRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; INTESTINE ABSORPTION; ION TRAP MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PROCESS DEVELOPMENT; RAT; TANDEM MASS SPECTROMETRY; ANIMAL; BIOAVAILABILITY; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT; TRANSPORT AT THE CELLULAR LEVEL;

ACYCLOVIR; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CHROMATOGRAPHY, LIQUID; DIPEPTIDES; ESTERS; GANCICLOVIR; INTESTINAL ABSORPTION; MALE; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY;

EID: 84940611851     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-014-0200-2     Document Type: Article

References (39)

1. Acosta EP, Fletcher CV (1997) Valacyclovir. Ann Pharmacother 31(2):185-191
2. Anand BS, Mitra AK (2002) Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea. Pharm Res 19(8):1194-1202
3. Atluri H, Anand BS, Patel J, Mitra AK (2004) Mechanism of a model dipeptide transport across blood-ocular barriers following systemic administration. Exp Eye Res 78(4):815-822
4. Balfour HH Jr, Kelly JM, Suarez CS, Heussner RC, Englund JA, Crane DD, McGuirt PV, Clemmer AF, Aeppli DM (1990) Acyclovir treatment of varicella in otherwise healthy children. J Pediatr 116(4):633-639
5. Bean B, Aeppli D (1985) Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster. J Infect Dis 151(2):362-365
6. Black ME, Newcomb TG, Wilson HM, Loeb LA (1996) Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci USA 93(8):3525-3529
7. Cheng YC, Grill SP, Dutschman GE, Nakayama K, Bastow KF (1983) Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells. J Biol Chem 258(20):12460-12464
8. Cheng YC, Grill SP, Dutschman GE, Frank KB, Chiou JF, Bastow KF, Nakayama K (1984) Effects of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new antiherpesvirus compound, on synthesis of macromolecules in herpes simplex virus-infected cells. Antimicrob Agents Chemother 26(3):283-288
9. Cholkar K, Patel SP, Vadlapudi AD, Mitra AK (2013) Novel strategies for anterior segment ocular drug delivery. J Ocular Pharmacol Ther 29(2):106-123. doi: 10.1089/jop.2012.0200
10. Crumpacker CS (1996) Ganciclovir. N Engl J Med 335(10):721-729. doi: 10.1056/NEJM199609053351007
11. De Clercq E (1993) Antivirals for the treatment of herpesvirus infections. J Antimicrob Chemother 32(Suppl A):121-132
12. Earla R, Cholkar K, Gunda S, Earla RL, Mitra AK (2012) Bioanalytical method validation of rapamycin in ocular matrix by QTRAP LC-MS/MS: application to rabbit anterior tissue distribution by topical administration of rapamycin nanomicellar formulation. J Chromatogr B Anal Technol Biomed Life Sci 908:76-86. doi: 10.1016/j.jchromb.2012.09.014
13. Earla R, Ande A, McArthur C, Kumar A, Kumar S (2014) Enhanced nicotine metabolism in HIV-1-positive smokers compared with HIV-negative smokers: simultaneous determination of nicotine and its four metabolites in their plasma using a simple and sensitive electrospray ionization liquid chromatography-tandem mass spectrometry technique. Drug Metab Dispos 42(2):282-293. doi: 10.1124/dmd.113.055186
14. Ernst ME, Franey RJ (1998) Acyclovir- and ganciclovir-induced neurotoxicity. Ann Pharmacother 32(1):111-113
15. Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK, St Louis ME (1997) Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 337(16):1105-1111. doi: 10.1056/NEJM199710163371601
16. Frank KB, Chiou J-F, Cheng Y (1984) Interaction of herpes simplex virus induced DNA polymerase with 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate. J Biol Chem 259:1566-1569
17. Freeman S, Gardiner JM (1996) Acyclic nucleosides as antiviral compounds. Mol Biotechnol 5(2):125-137. doi: 10.1007/BF02789061
18. Gnann JW Jr, Barton NH, Whitley RJ (1983) Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications. Pharmacotherapy 3(5):275-283
19. Goldmeier D, Johnson A, Byrne M, Barton S (1988) Psychosocial implications of recurrent genital herpes simplex virus infection. Genitourin Med 64(5):327-330
20. Hamzeh FM, Lietman PS (1991) Intranuclear accumulation of subgenomic noninfectious human cytomegalovirus DNA in infected cells in the presence of ganciclovir. Antimicrob Agents Chemother 35(9):1818-1823
21. Hamzeh FM, Lietman PS, Gibson W, Hayward GS (1990) Identification of the lytic origin of DNA replication in human cytomegalovirus by a novel approach utilizing ganciclovir-induced chain termination. J Virol 64(12):6184-6195
22. Hellden A, Lycke J, Vander T, Svensson JO, Odar-Cederlof I, Stahle L (2006) The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment. J Antimicrob Chemother 57(5):945-949. doi: 10.1093/jac/dkl067
23. Luby JP, Gnann JW Jr, Alexander WJ, Hatcher VA, Friedman-Kien AE, Klein RJ, Keyserling H, Nahmias A, Mills J, Schachter J et al (1984) A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo. J Infect Dis 150(1):1-6
24. Majumdar S, Gunda S, Mitra A (2003) Functional expression of a sodium dependent nucleoside transporter on rabbit cornea: role in corneal permeation of acyclovir and idoxuridine. Curr Eye Res 26(3-4):175-183
25. Majumdar S, Nashed YE, Patel K, Jain R, Itahashi M, Neumann DM, Hill JM, Mitra AK (2005) Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations. J Ocular Pharmacol Ther 21(6):463-474
26. Manne S, Sandler I (1984) Coping and adjustment to genital herpes. J Behav Med 7(4):391-410
27. Martin JC, Dvorak CA, Smee DF, Matthews TR, Verheyden JP (1983) 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. J Med Chem 26(5):759-761
28. Moolten FL, Wells JM (1990) Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 82(4):297-300
29. Nichols WG, Boeckh M (2000) Recent advances in the therapy and prevention of CMV infections. J Clini Virol 16(1):25-40
30. Perazella MA (1999) Crystal-induced acute renal failure. Am J Med 106(4):459-465
31. Perry CM, Faulds D (1996) Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 52(5):754-772
32. Razonable RR (2011) Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc 86(10):1009-1026
33. Smee DF, Martin JC, Verheyden JP, Matthews TR (1983) Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrob Agents Chemother 23(5):676-682
34. Smythe WR, Hwang HC, Elshami AA, Amin KM, Eck SL, Davidson BL, Wilson JM, Kaiser LR, Albelda SM (1995) Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 222(1):78-86
35. Tirucherai GS, Dias C, Mitra AK (2002) Corneal permeation of ganciclovir: mechanism of ganciclovir permeation enhancement by acyl ester prodrug design. J Ocular Pharmacol Ther 18(6):535-548. doi: 10.1089/108076802321021081
36. Vile RG, Hart IR (1993) Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 53(17):3860-3864
37. Wade JC, Meyers JD (1983) Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation. Ann Intern Med 98(6):921-925
38. Wallace MR, Bowler WA, Murray NB, Brodine SK, Oldfield EC 3rd (1992) Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial. Ann Intern Med 117(5):358-363
39. Wiltshire H, Hirankarn S, Farrell C, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Valganciclovir Solid Organ Transplant Study G (2005) Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 44(5):495-507